Oxford BioDynamics Plc has hired Bartu Ahiska to lead the commercialisation of the UK company’s EpiSwitch, a platform for discovering and evaluating the type of epigenetic biomarkers known as ‘chromosome conformation signatures’ (CCSs). He joins OBD from the Knight Cancer Early Detection Advanced Research Centre (CEDAR) at Oregon Health & Science University (OHSU), US. He holds a PhD in Computational Genomics from Oxford University and a MEng and MA in Information and Electronic Engineering from Cambridge University, both UK.
Oxford BioDynamics announced the appointment on 13 June 2019.
Copyright 2019 Evernow Publishing Ltd